Literature DB >> 7646556

Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice.

F Pinot1, D F Grant, J L Spearow, A G Parker, B D Hammock.   

Abstract

Soluble epoxide hydrolase (sEH) activity was measured in the liver and kidneys of male, female, and castrated male mice in order to evaluate sex- and tissue-specific differences in enzyme expression. sEH activity was found to be higher in liver than in kidneys. Activity increased with age in the liver of females, males and castrated males, but only in males did activity in the kidneys increase. There was greater activity in both the liver and kidneys of adult males than females. This sexual dimorphism was more pronounced in the kidneys (283% higher) than in the liver (55% higher). Castration of males led to a decrease in activity in both organs, but it had a greater effect on renal activity (67% decrease) than on hepatic activity (27% decrease). Treatment of castrated mice with testosterone led to an increase in sEH activity of 400% in kidneys and 49% in liver compared with surgical controls. These results suggest differential regulation of sEH by testosterone in kidneys and liver. Ovariectomized female mice had renal and hepatic activities approximately 30% greater than control females. Feeding mice with the hypolipidemic drug clofibrate produced stronger induction of sEH in liver than in kidneys. Testosterone treatment, however, caused greater induction in kidneys than in liver of females and castrated males and had no effect in either kidneys or liver in males. When given together, the effects of these two compounds appeared to be additive in both liver and kidneys. Results from western blot showed that the increase in sEH enzyme activity in kidneys is correlated with an increase in sEH protein. These results suggest that clofibrate and testosterone independently regulate sEH activity in vivo, and that kidneys and liver respond differently to clofibrate and testosterone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7646556     DOI: 10.1016/0006-2952(95)00167-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  29 in total

1.  Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.

Authors:  Paula Vainio; Santosh Gupta; Kirsi Ketola; Tuomas Mirtti; John-Patrick Mpindi; Pekka Kohonen; Vidal Fey; Merja Perälä; Frank Smit; Gerald Verhaegh; Jack Schalken; Kalle A Alanen; Olli Kallioniemi; Kristiina Iljin
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 2.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.

Authors:  Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2018-11-14       Impact factor: 11.685

Review 3.  Soluble epoxide hydrolase inhibitors and heart failure.

Authors:  Hong Qiu; Ning Li; Jun-Yan Liu; Todd R Harris; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Cardiovasc Ther       Date:  2011-04       Impact factor: 3.023

4.  Characterization of epoxide hydrolase activity in Alternaria alternata f. sp. lycopersici. Possible involvement in toxin production.

Authors:  F Pinot; E D Caldas; C Schmidt; D G Gilchrist; A D Jones; C K Winter; B D Hammock
Journal:  Mycopathologia       Date:  1997       Impact factor: 2.574

Review 5.  Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases.

Authors:  Jogen Atone; Karen Wagner; Kenji Hashimoto; Bruce D Hammock
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-11-05       Impact factor: 3.072

6.  Regional differences in sexually dimorphic protein expression in the spontaneously hypertensive rat (SHR).

Authors:  Douglas S Martin; Olga Klinkova; Kathleen M Eyster
Journal:  Mol Cell Biochem       Date:  2011-10-26       Impact factor: 3.396

7.  Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension.

Authors:  Kimberly Gilbert; Hui Nian; Chang Yu; James M Luther; Nancy J Brown
Journal:  J Hypertens       Date:  2013-04       Impact factor: 4.844

8.  Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia.

Authors:  Ines P Koerner; Wenri Zhang; Jian Cheng; Susan Parker; Patricia D Hurn; Nabil J Alkayed
Journal:  Front Biosci       Date:  2008-01-01

9.  Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2.

Authors:  Hiromasa Tanaka; Shizuo G Kamita; Nicola M Wolf; Todd R Harris; Zhaoju Wu; Christophe Morisseau; Bruce D Hammock
Journal:  Biochim Biophys Acta       Date:  2007-12-03

10.  Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase.

Authors:  Ayala Luria; Christophe Morisseau; Hsing-Ju Tsai; Jun Yang; Bora Inceoglu; Bart De Taeye; Steven M Watkins; Michelle M Wiest; J Bruce German; Bruce D Hammock
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-05-19       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.